Fortrea Holdings (FTRE) Share-based Compensation (2022 - 2026)
Fortrea Holdings (FTRE) reported Share-based Compensation of $11.4 million for Q1 2026, down 21.92% on a YoY basis from $14.6 million in Q1 2025, and down 22.97% quarter-over-quarter from $14.8 million in Q4 2025.
Fortrea Holdings (FTRE) Share-based Compensation (2022 - 2026) Analysis & Trends
Fortrea Holdings has reported Share-based Compensation for 5 years, with the latest figure at $11.4 million in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation fell 21.92% year-over-year to $11.4 million; the trailing twelve-month figure through Mar 2026 stood at $71.2 million (up 22.97% YoY), and the FY2025 full-year result was $74.4 million, up 27.4% from the prior year.
- Share-based Compensation for Q1 2026 stood at $11.4 million, down from $14.8 million in the prior quarter.
- The five-year high for Share-based Compensation was $22.7 million in Q2 2025, with the low at $5.8 million in Q4 2022.
- Historically, Share-based Compensation has averaged $13.3 million across 5 years, with a median of $14.6 million in 2025.
- Annual changes were most pronounced in 2023 — Share-based Compensation jumped 167.24% — and 2026, when it decreased 21.92%.
- Fortrea Holdings' Share-based Compensation stood at $5.8 million in 2022, then jumped by 167.24% to $15.5 million in 2023, then declined by 1.29% to $15.3 million in 2024, then decreased by 3.27% to $14.8 million in 2025, then decreased by 22.97% to $11.4 million in 2026.
- The last three Share-based Compensation figures came in at $11.4 million (Q1 2026), $14.8 million (Q4 2025), and $22.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 26.47 Mn |
| 10 | Fortrea Holdings | 1.43 Bn | 1.28 Bn | 123.60 Mn | 11.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.40 Mn |
| Mar 31, 2026 | 11.40 Mn |
| Dec 31, 2025 | 14.80 Mn |
| Dec 31, 2025 | 14.80 Mn |
| Sep 30, 2025 | 22.30 Mn |
| Sep 30, 2025 | 22.30 Mn |
| Jun 30, 2025 | 22.70 Mn |
| Jun 30, 2025 | 22.70 Mn |
| Mar 31, 2025 | 14.60 Mn |
| Mar 31, 2025 | 14.60 Mn |
| Dec 31, 2024 | 15.30 Mn |
| Dec 31, 2024 | 15.30 Mn |
| Sep 30, 2024 | 13.00 Mn |
| Sep 30, 2024 | 13.00 Mn |
| Jun 30, 2024 | 15.00 Mn |
| Jun 30, 2024 | 15.00 Mn |
| Mar 31, 2024 | 15.10 Mn |
| Mar 31, 2024 | 15.10 Mn |
| Dec 31, 2023 | 15.50 Mn |
| Dec 31, 2023 | 15.50 Mn |